EPGL Discussion 08/31/2014 04:24:10 $EPGL Both deals would

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
EPGL Discussion 08/31/2014 04:24:10 $EPGL
Both deals would be great, but contact lenses are a huge billion dollar business. Think about it. People that wear contact lenses have to buy new lenses almost every 30-45 days. That is constant repeat business for life. If the contact are $100 per 30 days that is $1,200 a year.

You will spend a lot more on contacts in a year than a person will spend on technology. When you pioneer a new contact lens technology that is tech based. Oh baby!!! This is absolutely huge.

EPGL is not a penny stock. It is a multiple dollar stock.
Have you done your revenue forecast for EPGL?

EPGL Stock Message Board http://investorshangout.com/EP-Global-Communi...PGL-87206/

I think within the next 2 weeks when cooper
announces the deal to their shareholders we see
that parabolic rise you've been talking about. I personally
think 2 dollars is not out of range this year.
I remember that- third law of thermodynamics stuffs.

Epgl
When you got some of the best talent in the world assembled into a company with the worlds largest accounting firm and insiders controlling the O/S that's the 1st sign of legit, then you look at zero toxic debt, zero dilution, real technology 2nd sign legit, next we have filling showing a major development agreement with a top lens manufacturer & distributer COO that is sign 3 this is legit and confirms EPGL as valid and legit. Now if some continue to argue EPGL is a scam, well to say it nicely they look silly!
Lmfaorotff as they would say lol

$$$$ EPGL $$$$
Thanks Viking for all your posts and encouragement
throughout the last years. People have told me to sell
but I just kept doing more DD and now I have accumulated
over 2 million shares and told countless people . My friend
who trades stock everyday told me yesterday that I was
right all along when he doubted all the time. Now
he's investing Tuesday. Go Epgl
From last August...I think EPGL & COO are further along in development then most of us realize.

Quote:
We now have the ability to use MEMS to put the technology into the micro size environment for contact lenses. This technology will be incorporated into therapeutic contact lenses which will emit a low, safe dose of the ultrasound energy into the eye on a regular basis for the purpose of slowing or arresting the development of macular degeneration, retinitis pigmentosa and other eye disorders," said David T. Markus, PhD. "We want to pioneer the area of therapeutic contact lenses and we can see a tremendous market size and need going into the future for this technology."



About David T. Markus, Ph.D. Vice President - BioMems Development

David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. Dr. Markus spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world's leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He was a principal investigator on SBIR DARPA Phase I and Phase II, and "Ultraflexible Substrate" for Macroelectronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery. Finally, Dr. Markus is fluent in English, Chinese-Madarin, Taiwanese-FuJian and Indonesian languages.





The contact lens market is huge market, make them smart and this market will grow 10-fold, best part is Cooper now leads the race as EPGL advanced technology has given them the only self contained self powered source of energy, they now have the technology to bring these lenses to market!

EPGL is leading giants, make no mistake about it!

$$$ EPGL $$$

$$$ COO $$$$
Not only does EPGL have a confirmed deal with COO, they are in discussions with other major players in consumer electronics!!

We could be talking Apple, Google, Samsung, Amazon and many others in future deals!


If they can make a deal in this sector, this will be much bigger than contact lens deal, imho. That will be huge. Google, apple, Facebook comes in mind.

Let's see. I am excited.

Epgl
Also, EPGL is currently in discussions with more than one major company to secure rights to its technologies in the consumer electronics and communications field


I agree. I am wondering what some of those folks, who said Epgl a scam in this board before, are thinking now. Looks like they missed the opportunity to buy in cheap, imho.

Epgl
Just one of Coopers products could mean billions in future sales, YES BILLIONS, this means huge revenues for both COO & EPGL!


EPGL is supplying the technology for these advanced products, what happens when we see licensing agreements to other major companies put in place?

EPGL is much more then a .077 OTC stock, soon we will be trading .10+, then work towards .25+ in time DOLLARS

$$$$ EPGL $$$$
Right. That was back in the days of the MPDD and muscle pain treatment devices. Obviously the MPDD is still being manufactured, marketed and sold.

With the much more recent tech I see no reason why this isn't a 50-100 billion company in 3-5 years. So yeah, I'm calling it: $10-$20 a share in 3-5 years. Mark this post.
Absolutely right. There are some of us longs that have been EPGL Shareholders for 4-5+ years now. If 100's of thousands in swings in a single day, week, month or year haven't made us sell yet, guess what these small movements won't any time soon.
There are hundreds of millions held long that will stay that way for years yet in my very strong opinion.
EPGL will be a life changer for customers and shareholders alike.
THIS IS NOT A PINKSHEET COMPANY. It is just a short entry level buying opportunity of a future blue chip.

Quote:
L2 hasn't been perfect for this stock. With the expectations held by the longs on this board 1-2cents doesn't bother us (the majority at least). With multiple $s on the way what's the difference between $1.20 and $1.22? Only $16000 for me out of a total of ~$850000. I'd rather not risk waiting for a dip and missing the run.

From all that's been said it's safe to say the product is near completion with coo. With the added bonus of additional partners within a short period of time by September next year we'll be at $1+. Probably sooner if you take into account ray kurzweils 'Singularity' and the timeline the future holds based in the past thousands of years. It's all out there to study.

Sometime back in one of the CCs , ceo said, he would value epgl at $2 if this was a private company. That was way before the valuation of Epgl's current IPs and of course these current developments. I am wondering what valuation is he thinking now.

This can be a life changing opportunity for longs, imho. Time will tell. Glad to be a shareholder from 2009-2010.

Epgl
Time to get in EPGL is before this deal is more widely exposed to analysts, EPGL was .082 before close and painted .077 to close. Trend is clearly up wayyyyy up, just look at chart. EPGL will break past .10 next week in my strong opinion. I have had good response from big time money players they will find a spot


Retrace to .10 coming, find your spot before big money takes it higher, much higher, know what you own With EPGL

$$$$$ EPGL $$$$$$
$EPGL
#COO
#MEMS

September is going to be a month filled with "Holy shit!" and "yee-haaa!"... okay and the occasional "WTF!"
EPGL
"Like"
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
More News Articles